Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Supernus Pharmaceuticals, Inc. (SUPN)

33.08   0.14 (0.43%) 09-24 16:18
Open: 32.91 Pre. Close: 32.94
High: 33.14 Low: 32.15
Volume: 429,434 Market Cap: 1,770(M)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 33.16 - 33.36 33.36 - 33.55
Low: 31.68 - 31.91 31.91 - 32.14
Close: 32.72 - 33.07 33.07 - 33.4

Technical analysis

as of: 2022-09-23 4:27:48 PM
Overall:       
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 40.38     One year: 42.14
Support: Support1: 32.15    Support2: 26.74
Resistance: Resistance1: 34.57    Resistance2: 36.08
Pivot: 34.41
Moving Average: MA(5): 34.05     MA(20): 34.33
MA(100): 30.48     MA(250): 30.5
MACD: MACD(12,26): 0.1     Signal(9): 0.4
Stochastic oscillator: %K(14,3): 23.8     %D(3): 40
RSI: RSI(14): 42.6
52-week: High: 36.08  Low: 24.95
Average Vol(K): 3-Month: 376 (K)  10-Days: 410 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SUPN ] has closed below the lower bollinger band by 2.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ SUPN ] is to continue within current trading range. Bollinger Bands are 22.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 23 Sep 2022
Will Supernus Pharmaceuticals Inc (SUPN) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Tue, 20 Sep 2022
Here Are a Few Trading Dice to Consider Rolling Ahead of the Fed's Rate News - RealMoney

Wed, 31 Aug 2022
Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Increased to $38.00 by Analysts at Piper Sandler - MarketBeat

Fri, 19 Aug 2022
Supernus Pharmaceuticals Stock: Eyes On Qelbree Launch (NASDAQ:SUPN) - Seeking Alpha

Tue, 16 Aug 2022
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear - Simply Wall St

Sun, 07 Aug 2022
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 54 (M)
Shares Float 47 (M)
% Held by Insiders 4.6 (%)
% Held by Institutions 105.3 (%)
Shares Short 5,580 (K)
Shares Short P.Month 5,580 (K)

Stock Financials

EPS 1
EPS Est Next Qtl 0.25
EPS Est This Year 1.03
EPS Est Next Year 1.65
Book Value (p.s.) 15.72
Profit Margin (%) 9.1
Operating Margin (%) 13
Return on Assets (ttm) 3.1
Return on Equity (ttm) 7
Qtrly Rev. Growth 20.2
Gross Profit (p.s.) 9.43
Sales Per Share 11.77
EBITDA (p.s.) 2.69
Qtrly Earnings Growth -66.9
Operating Cash Flow 120 (M)
Levered Free Cash Flow 145 (M)

Stock Valuations

PE Ratio 32.75
PEG Ratio 0
Price to Book value 2.1
Price to Sales 2.8
Price to Cash Flow 14.73

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.